Scholarlink

Background <p>Infections due to <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> are common in the hospital setting and carry a high risk for morbidity and mortality. Furthermore, the incidence of drug-resistant phenotypes, such as vancomycin-resistant Enterococci (VRE) and daptomycin non-susceptible strains, is increasing. Eravacycline (ERV) is a novel tetracycline antibiotic approved for the treatment of complicated intra-abdominal infections and possesses a broad spectrum of activity across both Gram-positive and Gram-negative organisms, including VRE, methicillin-resistant <i>Staphylococcus aureus</i>, and carbapenem-resistant Enterobacterales.</p> Methods <p>We conducted a subgroup analysis assessing the real-world efficacy and safety of ERV for the treatment of enterococcal infections. Adult patients who received ERV for ≥ 72&#xa0;h for <i>E. faecalis</i> or <i>E. faecium</i> infections were included. The primary outcome of clinical cure was defined as resolution or improvement of infection-related signs and/or symptoms.</p> Results <p>A total of 100 patients were included in the analysis. <i>E. faecalis</i> and <i>E. faecium</i> were present in 44% and 58% of patients, respectively, and 49% of all isolates were VRE. The most prevalent infection types were intra-abdominal, skin/soft tissue, and osteomyelitis, and a majority (80%) of infections were polymicrobial. Clinical cure was achieved in 77% of patients. Thirty-day mortality was 17% and 30-day infection-related mortality was 12%. Thirty-day hospital readmission rate was 14%, and microbiological recurrence occurred in 4% of patients. Treatment-emergent adverse events occurred in 8% of patients, with 2% of patients requiring discontinuation of ERV.</p> Conclusion <p>This study describes the real-world safety and efficacy of ERV for the treatment of enterococcal infections.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical efficacy and safety of eravacycline for the treatment of enterococcal infections: a subpopulation analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月29日

查看全文
  • Sean R. Van Helden,
  • Ashlan J. Kunz Coyne,
  • Sara Alosaimy,
  • Kyle C. Molina,
  • S. Lena Kang-Birken,
  • Justin Andrade,
  • Madeline A. King,
  • Kimberly C. Claeys,
  • Athena L. V. Hobbs,
  • Nicholson B. Perkins III,
  • Jazmin Agee,
  • Alaina DeKerlegand,
  • Mark Biagi,
  • Michael P. Veve,
  • Serina Tart,
  • Tristan Gore,
  • Bruce M. Jones,
  • Benjamin M. Pullinger,
  • Melanie Rae Schrack,
  • Reese Cosimi,
  • Shelbye R. Herbin,
  • Chloe Judd,
  • Mohammed Al Musawa,
  • Michael J. Rybak

摘要

Background

Infections due to Enterococcus faecalis and Enterococcus faecium are common in the hospital setting and carry a high risk for morbidity and mortality. Furthermore, the incidence of drug-resistant phenotypes, such as vancomycin-resistant Enterococci (VRE) and daptomycin non-susceptible strains, is increasing. Eravacycline (ERV) is a novel tetracycline antibiotic approved for the treatment of complicated intra-abdominal infections and possesses a broad spectrum of activity across both Gram-positive and Gram-negative organisms, including VRE, methicillin-resistant Staphylococcus aureus, and carbapenem-resistant Enterobacterales.

Methods

We conducted a subgroup analysis assessing the real-world efficacy and safety of ERV for the treatment of enterococcal infections. Adult patients who received ERV for ≥ 72 h for E. faecalis or E. faecium infections were included. The primary outcome of clinical cure was defined as resolution or improvement of infection-related signs and/or symptoms.

Results

A total of 100 patients were included in the analysis. E. faecalis and E. faecium were present in 44% and 58% of patients, respectively, and 49% of all isolates were VRE. The most prevalent infection types were intra-abdominal, skin/soft tissue, and osteomyelitis, and a majority (80%) of infections were polymicrobial. Clinical cure was achieved in 77% of patients. Thirty-day mortality was 17% and 30-day infection-related mortality was 12%. Thirty-day hospital readmission rate was 14%, and microbiological recurrence occurred in 4% of patients. Treatment-emergent adverse events occurred in 8% of patients, with 2% of patients requiring discontinuation of ERV.

Conclusion

This study describes the real-world safety and efficacy of ERV for the treatment of enterococcal infections.